查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
血脂異常藥物市場，按藥物類別、按應用、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1388770

血脂異常藥物市場，按藥物類別、按應用、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Dyslipidemia Drugs Market, By Drug Class, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 269 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年血脂異常藥物市場規模為156.5343億美元，2023年至2030年複合CAGR為5.5%。

血脂異常是患者普遍存在的疾病，對心血管疾病的發生和進展構成重大風險。這些疾病的特徵是總膽固醇（TC）、三酸甘油酯（TG）和低密度脂蛋白膽固醇（LDL-C）含量升高。血脂異常藥物用於治療這種疾病，這種疾病的定義是血液中脂質（脂肪）含量異常。降低膽固醇含量的治療基石包括傳統的降血脂療法（LLT），例如他汀類藥物、ezetimibe和 PCSK9 抑制劑，並結合維持健康的生活方式。他汀類藥物透過選擇性抑制 HMG-CoA 還原酶來降低細胞膽固醇含量。

血脂異常藥物市場-市場動態

久坐的生活方式、不健康的飲食習慣和肥胖的盛行率不斷增加

由於久坐的生活方式、不健康的飲食習慣、肥胖等因素，血脂異常的發生率增加。隨著社會經濟發展導致生活方式進一步改變，這種趨勢預計將持續下去。根據國家生物技術資訊中心的資料，目前血脂異常的盛行率為66.7%，其中高LDL-C、高三酸甘油酯、高總膽固醇和低HDL-C的盛行率分別為49.5%、40.2%、30.8%和分別為 16.5%。血脂異常藥物市場預計將成長，以滿足對有效治療不斷成長的需求。此外，藥物配方和作用機制的創新為新型和增強藥物帶來了前景。然而，替代療法的可用性可能會阻礙市場成長。

血脂異常藥物市場 - 關鍵見解

  • 根據研究分析師的分析，全球血脂異常藥物市場預計在預測期內（2023-2030）每年將以 5.5%左右的CAGR成長
  • 由於久坐的生活方式、不健康的飲食習慣和肥胖的流行，預計對血脂異常治療的需求將顯著成長
  • 根據藥物類別細分，預計他汀類藥物在2022年佔據最大市場佔有率
  • 從應用細分來看，醫院藥局是2022年的主導類型
  • 依地區分類，北美是2022年的主要收入來源

血脂異常藥物市場-細分分析：

全球血脂異常藥物市場根據藥物類別、應用和地區進行細分。

市場依藥物類別分為兩類：非他汀類藥物和他汀類藥物。他汀類藥物在市場上佔據主導地位。他汀類藥物是治療血脂異常的常用藥物，特別是在控制膽固醇含量升高方面。它們在降低 LDL（低密度脂蛋白）膽固醇（俗稱壞膽固醇）方面非常有效，因此是治療這種疾病最常用的藥物之一。

根據應用市場分為三類：醫院藥局、零售藥局和其他。醫院藥房佔據市場主導地位。血脂異常藥物的管理和應用在醫院環境中非常重要，因為患有心血管疾病（包括血脂異常）的患者通常從醫院藥房接受初始或持續治療。

血脂異常藥物市場-地理洞察

該市場廣泛覆蓋北美、歐洲、亞太地區、拉丁美洲、中東和非洲。這些區域根據進行商業活動的國家進一步細分。由於生物技術的進步和醫療設施的升級，北美可能會引領血脂異常藥物市場的擴張。北美的醫療基礎設施高度發達，技術先進，有助於有效診斷、治療和控制血脂異常等一系列疾病。 《全球視野下的美國醫療保健》顯示，2021年，美國醫療支出佔GDP的17.8%，幾乎是經合組織國家中位數的兩倍。此外，該地區生物技術和製藥公司也大量集中，目前進行廣泛的研究和開發活動。由於對血脂異常藥物研發的投資不斷增加，歐洲是第二大血脂異常藥物市場。

血脂異常藥物市場-競爭格局：

藥品行銷服務（PMS）對於製藥公司非常重要，因為它們在公司和醫生之間建立了聯繫。他們還充當本地和全球醫生和患者之間的橋樑。血脂異常藥物的競爭格局包括著名的製藥公司、其主要產品、市場佔有率以及解決這種疾病的策略。在這個競爭激烈的市場中，策略包括持續的研究和開發努力，以創造更有效和更安全的藥物，積極的行銷活動以影響醫生和患者，以及戰略合作以加強市場主導地位。

最近的發展：

2023年7月，諾華表示，美國FDA 已授權對Leqvio（inclisiran）的標籤進行修改，以便更早地將其作為飲食和他汀類藥物治療的補充，用於心臟病風險較高的高LDL-C患者。

目錄

第1章：血脂異常藥物市場概述

  • 研究範圍
  • 市場預估年份

第2章：執行摘要

  • 市場摘要
    • 依藥物類別分類的血脂異常藥物市場摘要
    • 依應用分類的血脂異常藥物市場摘要
    • 依國家分類的血脂異常藥物市場摘要
    • 依地區分類的血脂異常藥物市場摘要
  • 競爭洞察

第3章：血脂異常藥物主要市場趨勢

  • 血脂異常藥物市場促進因素
    • 市場促進因素的影響分析
  • 血脂異常藥物市場限制
    • 市場限制影響分析
  • 血脂異常藥物市場機會
  • 血脂異常藥物市場未來趨勢

第4章：血脂異常藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：血脂異常藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章：血脂異常藥物市場格局

  • 2022年血脂異常藥物市佔分析
  • 細分資料：按主要製造商
    • 既有參與者分析
    • 新興參與者分析

第7章：血脂異常藥物市場 - 依藥物類別

  • 概述
    • 依藥物類別分類的細分市場佔有率分析
    • 非他汀類藥物
      • 膽汁酸螯合劑
      • 膽固醇吸收抑制劑
      • 貝特類
      • 菸鹼酸
      • 其他
    • 他汀類藥物
      • 高強度
      • 中等強度
      • 低強度

第8章：血脂異常藥物市場 -依應用

  • 概述
    • 依應用的細分市場佔有率分析
    • 醫院藥房
    • 零售藥房
    • 其他

第9章：血脂異常藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美血脂異常藥物主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依藥物類別）
    • 北美市場規模和預測（依應用）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲血脂異常藥物主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依藥物類別）
    • 歐洲市場規模和預測（依應用）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區血脂異常藥物主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模和預測（依藥物類別）
    • 亞太地區市場規模與預測（依應用）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲血脂異常藥物主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依藥物類別）
    • 拉丁美洲市場規模與預測（依應用）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲血脂異常藥物主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依藥物類別）
    • 中東和非洲市場規模及預測（依應用）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第10章：主要供應商分析 - 血脂異常藥物產業

  • 競爭儀表板
  • 公司簡介
    • Novartis AG
    • Mylan NV
    • Bristol-Myers Squibb Company
    • AstraZeneca plc
    • Shionogi & Co., Ltd.
    • Pfizer, Inc.
    • Abbott Laboratories.
    • Merck & Co., Inc.
    • Bayer AG
    • Amgen, Inc.

第11章：360 度分析師視角

第12章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1824

REPORT HIGHLIGHT

Dyslipidemia Drugs Market size was valued at USD 15,653.43 Million in 2022, expanding at a CAGR of 5.5% from 2023 to 2030.

Dyslipidemias, prevalent disorders among patients, pose significant risks for the development and progression of cardiovascular diseases. These disorders are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C). Medications known as dyslipidemia drugs are utilized to treat this medical condition, which is defined by abnormal lipid (fat) levels in the bloodstream. The cornerstone of treatment to lower cholesterol levels involves conventional lipid-lowering therapies (LLTs), such as statins, ezetimibe, and PCSK9 inhibitors, in conjunction with maintaining a healthy lifestyle. Statins work by reducing cellular cholesterol content through the selective inhibition of the enzyme HMG-CoA reductase.

Dyslipidemia Drugs Market- Market Dynamics

Increasing Prevalence of sedentary lifestyles, unhealthy dietary habits, and obesity

The incidence of dyslipidemia has increased due to factors such as sedentary lifestyles, unhealthy dietary habits, and obesity. This trend is expected to continue as socio-economic development leads to further lifestyle changes. According to the National Center for Biotechnological Information, the prevalence of dyslipidemia is currently at 66.7%, with high LDL-C, elevated triglyceride, elevated total cholesterol, and low HDL-C being prevalent in 49.5%, 40.2%, 30.8%, and 16.5% of cases, respectively. The dyslipidemia drugs market is expected to grow to meet the rising demand for effective treatments. Furthermore, Innovations in drug formulations and mechanisms of action present prospects for novel and enhanced medications. However, the availability of alternative therapies may hamper the market growth.

Dyslipidemia Drugs Market- Key Insights

  • As per the analysis shared by our research analyst, the global Dyslipidemia Drugs market is estimated to grow annually at a CAGR of around 5.5% over the forecast period (2023-2030)
  • The demand for dyslipidemia treatments is expected to grow significantly due to Increasing Prevalence of sedentary lifestyles, unhealthy dietary habits, and obesity
  • Based on Drug Class segmentation, statins drugs were predicted to show maximum market share in the year 2022
  • Based on Application segmentation, Hospital pharmacy was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Dyslipidemia Drugs Market- Segmentation Analysis:

The Global Dyslipidemia Drugs Market is segmented on the basis of Drug Class, Application, and Region.

The market is divided into two categories based on Drug Class: Non-statins drugs and statins drugs. statins drugs dominate the market. Statins are frequently prescribed drugs for the treatment of dyslipidemia, particularly in the management of elevated levels of cholesterol. They are highly effective in reducing LDL (low-density lipoprotein) cholesterol, commonly known as bad cholesterol, and are therefore one of the most commonly prescribed medications for this condition.

The market is divided into three categories based on Application: Hospital pharmacy, Retail pharmacy, and Others. Hospital pharmacy dominates the market. The management and Application of dyslipidemia drugs are of utmost importance in hospital settings, as patients with cardiovascular conditions, including dyslipidemia, often receive their initial or ongoing treatment from hospital pharmacies.

Dyslipidemia Drugs Market- Geographical Insights

This market is extensive over North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. These areas are further subdivided based on the countries bringing commerce. Because of biotechnological advancements and upgrades in healthcare facilities North America is likely to lead in the expansion of the Dyslipidemia Drugs market. The healthcare infrastructure in North America is highly developed and technologically advanced, facilitating the effective diagnosis, treatment, and control of a range of medical conditions, such as dyslipidemia. The U.S. Health Care from a Global Perspective showed that in 2021, the U.S. disbursed 17.8 % of GDP on medical care, nearly double as much as the median OECD nations. Also, there is a significant concentration of biotechnology and pharmaceutical firms in the area, which are currently involved in extensive research and development activities. Europe is the second largest Dyslipidemia Drugs market, due to growing investment in Research and development of Dyslipidemia Drugs.

Dyslipidemia Drugs Market- Competitive Landscape:

Pharmaceutical marketing services (PMS) are essential for pharmaceutical companies as they establish connections between the company and physicians. They also serve as a bridge between physicians and patients, both locally and globally. The competitive landscape of dyslipidemia drugs includes prominent pharmaceutical companies, their primary products, market share, and strategies to address this medical condition. In this competitive market, strategies involve continuous research and development efforts to create more effective and safer medications, assertive marketing campaigns to influence physicians and patients, and strategic collaborations to strengthen market dominance.

Recent Developments:

on July 2023, Novartis said that the US FDA had authorized a label modification for Leqvio (inclisiran) to allow for earlier usage as an addition to diet and statin treatment in patients with high LDL-C who are at greater risk of heart disease.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DYSLIPIDEMIA DRUGS MARKET KEY PLAYERS

  • Novartis AG
  • Mylan N.V.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Shionogi & Co., Ltd.
  • Pfizer, Inc.
  • Abbott Laboratories.
  • Merck & Co., Inc.
  • Bayer AG
  • Amgen, Inc.

GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY DRUG CLASS

  • Non-statins drugs
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitor
  • Fibrates
  • Nicotinic Acid
  • Others
  • Statin drugs
  • High intensity
  • Moderate intensity
  • Low intensity

GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY APPLICATION

  • Hospital pharmacy
  • Retail pharmacy
  • Others

GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Dyslipidemia Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Dyslipidemia Drugs Market Snippet by Drug Class
    • 2.1.2. Dyslipidemia Drugs Market Snippet by Application
    • 2.1.3. Dyslipidemia Drugs Market Snippet by Country
    • 2.1.4. Dyslipidemia Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Dyslipidemia Drugs Key Market Trends

  • 3.1. Dyslipidemia Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Dyslipidemia Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Dyslipidemia Drugs Market Opportunities
  • 3.4. Dyslipidemia Drugs Market Future Trends

4. Dyslipidemia Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Dyslipidemia Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Dyslipidemia Drugs Market Landscape

  • 6.1. Dyslipidemia Drugs Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Dyslipidemia Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 7.1.2. Non-statins drugs
      • 7.1.2.1. Bile Acid Sequestrants
      • 7.1.2.2. Cholesterol Absorption Inhibitor
      • 7.1.2.3. Fibrates
      • 7.1.2.4. Nicotinic Acid
      • 7.1.2.5. Others
    • 7.1.3. Statin drugs
      • 7.1.3.1. High intensity
      • 7.1.3.2. Moderate intensity
      • 7.1.3.3. Low intensity

8. Dyslipidemia Drugs Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
    • 8.1.2. Hospital pharmacy
    • 8.1.3. Retail pharmacy
    • 8.1.4. Others

9. Dyslipidaemia Drugs Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Dyslipidemia Drugs Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Dyslipidemia Drugs Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Dyslipidemia Drugs Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Dyslipidemia Drugs Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Dyslipidemia Drugs Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Dyslipidemia Drugs Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Novartis AG
    • 10.2.2. Mylan N.V.
    • 10.2.3. Bristol-Myers Squibb Company
    • 10.2.4. AstraZeneca plc
    • 10.2.5. Shionogi & Co., Ltd.
    • 10.2.6. Pfizer, Inc.
    • 10.2.7. Abbott Laboratories.
    • 10.2.8. Merck & Co., Inc.
    • 10.2.9. Bayer AG
    • 10.2.10. Amgen, Inc.

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Dyslipidemia Drugs Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Dyslipidemia Drugs Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Dyslipidemia Drugs Market: Application Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Dyslipidemia Drugs Market, by Application 2018-2030 (USD Million)
  • TABLE Dyslipidemia Drugs Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Dyslipidemia Drugs Market, by Region 2018-2030 (USD Million)
  • TABLE North America Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Europe Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Asia Pacific Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Latin America Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)

List of Figures

  • FIGURE Dyslipidemia Drugs Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Drug Class segment market share analysis, 2022 & 2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Application segment market share analysis, 2022 & 2030
  • FIGURE Application segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Dyslipidemia Drugs Market share and leading players, 2022
  • FIGURE Europe Dyslipidemia Drugs Market share and leading players, 2022
  • FIGURE Asia Pacific Dyslipidemia Drugs Market share and leading players, 2022
  • FIGURE Latin America Dyslipidemia Drugs Market share and leading players, 2022
  • FIGURE Middle East and Africa Dyslipidemia Drugs Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Dyslipidemia Drugs Market share analysis by country, 2022
  • FIGURE Germany Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Dyslipidemia Drugs Market share analysis by country, 2022
  • FIGURE India Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Dyslipidemia Drugs Market share analysis by country, 2022
  • FIGURE Brazil Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Dyslipidemia Drugs Market share analysis by country, 2022
  • FIGURE Saudi Arabia Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)